Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Amgen
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06333951CT.gov Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | — | Active Not Recruiting | — | — | — |
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT02909452CT.gov Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02587455CT.gov Pembrolizumab and Palliative Radiotherapy in Lung | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm Of Thorax
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Amgen | P3 | B · 60 |
| Carboplatin | Fundación GECP | P3 | BB |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Nanfang Hospital, Southern Medical University | P3 | B |
| Gefitinib | Chinese Society of Lung Cancer | P3 | B |
| Rivoceranib | Sichuan Cancer Hospital and Research Institute | P2 | B |
| Docetaxel | University of Turin, Italy | P3 | B |
| L-Bupivacaine | Guy's and St Thomas' NHS Foundation Trust | P2/3 | B |
| Vinorelbine Ditartrate | University of Turin, Italy | P3 | B |
+15 more in the Neoplasm Of Thorax cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Neoplasm Of Thorax. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-neoplasm-of-thorax
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →